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Unexpected Proatherogenic Properties of p21
Beyond Cell Cycle Control?
Vicente Andrés, PhD
Atherosclerosis is an inflammatory disease that in-volves the interplay between endothelial cells,smooth muscle cells (SMCs), and immune cells.1,2
Various atherogenic stimuli lead to endothelial damage,
which in turn triggers the adhesion and extravasation of
circulating monocytes and lymphocytes into the artery wall.
Resident immune cells produce a plethora of inflammatory
mediators that exacerbate leukocyte recruitment and prolifer-
ation and promote SMC growth and migration from the
underlying media toward the developing atheroma. Abnormal
cell proliferation and migration are also a hallmark of
neointimal thickening during postangioplasty restenosis,
transplant vasculopathy, and graft atherosclerosis.1,3
See p 3830
Mammalian cell cycle progression is governed by the
concerted activation of holoenzymes composed of a catalytic
cyclin-dependent protein kinase (CDK) and a regulatory
subunit named cyclin. Cell proliferation is constrained by the
interaction of CDK/cyclin holoenzymes with members of the
Cip/Kip (for CDK interacting protein/kinase inhibitory pro-
tein) and Ink4 (for inhibitor of CDK4) families of CDK
inhibitory proteins (CKIs).4 Ink4 proteins (p16Ink4a, p15Ink4b,
p18Ink4c, p19Ink4d) are thought to be specific for cyclin D–as-
sociated CDKs, whereas Cip/Kip proteins (p21Cip1/Waf1/Sdi1,
p27Kip1, p57Kip2) bind to and inhibit a wide spectrum of
CDK/cyclin complexes.
Role of Cell Cycle–Regulatory Factors in
Neointimal Thickening: Lessons Learned
From Animal Models
There is compelling evidence from animal studies that cell
cycle–regulatory factors are key modulators of neointimal
lesion development, at least in part through their ability to
regulate cell proliferation and locomotion.5,6 First, intralumi-
nal delivery of antisense oligonucleotides against several
CDKs and cyclins or pharmacological inhibition of CDK
activity efficiently reduced neointimal thickening after bal-
loon angioplasty and vascular grafting. Second, arterial ex-
pression of p21Cip1/Waf1/Sdi1 (p21) and p27Kip1 (p27) is induced at
late time points after angioplasty, coinciding with the rees-
tablishment of the quiescent phenotype, suggesting that
upregulation of these CKIs may limit neointimal hyperplasia.
Consistent with this notion, gene transfer of p21, p27, p57Kip2,
and p53, a tumor suppressor the action of which is mediated
under some circumstances by p21, efficiently attenuates
neointimal thickening induced by angioplasty and vessel
grafting. Third, the analysis of genetically modified mice has
revealed a protective role of p53 and p27 against diet-induced
atherosclerosis. Guevara et al7 first reported the effect of p53
ablation in atherosclerosis-prone apolipoprotein E (apoE)–
knockout mice and found that doubly deficient p53/apoE/
mice develop considerably accelerated aortic atherosclerosis
in response to a high-fat Western-type diet compared with
apoE-null mice with an intact p53 gene. p53/apoE/ mice
disclosed a significant increase in arterial cell proliferation
with no significant changes in apoptosis. The main findings
of this study have been extended by the demonstration that
reconstitution of irradiated LDL receptor–null mice8 or
apoE*3-Leiden transgenic mice9 with p53-null bone marrow–
derived cells also accelerates atherosclerosis. Likewise, p27
inactivation, either globally10 or in bone marrow–derived
cells,11 increases arterial cell proliferation and accelerates
arteriosclerosis in fat-fed apoE-null mice.
Absence of p21 Is Now Shown to Protect
Against Atherosclerosis in ApoE-Null Mice
The aforementioned studies highlight the role of CKIs and
p53 as negative regulators of neointimal thickening. In this
issue of Circulation, Merched and Chan12 report, surpris-
ingly, that mice doubly deficient for p21 and apoE (p21/
apoE/) maintained on a regular chow disclose reduced
aortic atherosclerosis compared with age-matched apoE-null
counterparts with an intact p21 gene (p21/apoE/) (53%
and 32% reduction at 5 and 14 months of age, respec-
tively). Similarly, mice maintained for 15 weeks on a high-fat
diet disclosed more aggressive atherosclerosis in the presence
of p21 expression (31% to 39% larger lesions in p21/
apoE/ versus p21/apoE/ mice). The authors went on to
examine the consequences of transplanting p21/apoE/ or
p21/apoE/ bone marrow into lethally irradiated apoE-null
mice and found a 32% reduction in atherosclerosis after
reconstitution with p21-null marrow. Thus, in contrast to the
reported intensification of atherosclerosis achieved on p27 or
p53 inactivation in different induced murine models,7–11
Merched and Chan12 convincingly establish that p21 ablation,
either globally or selectively in hematopoietic precursors,
reduces both spontaneous and diet-induced atherosclerosis in
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apoE-null mice examined at different ages and under differ-
ent nutritional regimens. Because transplantation of p21-null
bone marrow cells into irradiated apoE-null mice reproduced
most of the protective effect of whole-body p21 inactivation,
including a thicker and better-formed fibrous cap, it was
concluded that the absence of p21 expression in the neointi-
mal macrophages is important to the beneficial effect against
atherosclerosis.
Why p21 Disruption Protects ApoE-Null Mice
From Atherosclerosis
Merched and Chan12 performed a series of experiments that
provide mechanistic insight into the unexpected atheropro-
tective role of the absence of p21 in apoE-null mice: (1)
Atherosclerotic lesions in the absence of p21 expression
exhibited increased apoptosis, a higher level of scavenger
receptor type B-I (SR-BI) expression, and reduced inflamma-
tory vascular cell adhesion molecule-1 expression; (2)
thioglycolate-elicited peritoneal macrophages obtained from
p21-null mice disclosed higher expression of putative athero-
protective factors (ie, SR-BI, macrophage scavenger receptor
A, and LDL receptor–related protein) and lower levels of
proatherogenic molecules (ie, macrophage inflammatory pro-
teins 1 and 2, interleukin-1) than did wild-type counterparts;
and (3) p21-deficient macrophages displayed in culture in-
creased phagocytic activity toward fluorescent latex micro-
spheres as well as apoptotic thymocytes. Collectively, these
findings highlight new roles of p21 in macrophage function
and inflammatory response that may contribute to the athero-
genic activity of p21 expression in apoE-null mice.
Preservation of a quiescent, multipotential stem cell pool
capable of intermittently giving rise to highly proliferative
progenitors is essential for maintaining blood homeostasis.
Studies using knockout mice suggest that p27 and p21 play
distinct roles in regulating these events. Unlike p27, which
appears to govern stem cell repopulation efficiency but not
pool size,13 p21 has been proposed as the molecular switch
governing the entry of stem cells into the cell cycle, and
increased cell cycling in the absence of p21 leads to stem cell
exhaustion.14 Thus, determining whether stem cell deficiency
might contribute to reduced atherosclerosis in p21/apoE/
mice warrants examination. It is also noteworthy that specific
inhibition of p21 by transfer of antisense oligonucleotides
does not abolish the growth-inhibitory effect of transforming
growth factor- in cultured SMCs, yet it markedly reduces
both the synthesis and secretion of laminin and fibronectin.15
Thus, diminished matrix protein deposition may attenuate
atherosclerosis in p21/apoE/ mice.
Because excessive cell growth is thought to contribute to
atheroma development5,6 and p21 is generally considered a
growth suppressor,4 one must also reflect on cellular prolif-
eration when considering the provocative study by Merched
and Chan.12 The authors conducted bromodeoxyuridine
(BrdU) incorporation studies in 20-week-old mice fed a
normal chow diet and found no differences in plaque cell
proliferation when comparing p21/apoE/ and p21/
apoE/ mice. However, additional BrdU incorporation ex-
periments at different ages and different time points after the
onset of the atherogenic diet are warranted to precisely
establish the consequences of p21 inactivation on arterial cell
growth in this murine model. These supplementary studies
may reveal increased proliferation in the absence of p21 (ie,
at the very onset of atheroma development). Conversely, if no
differences in proliferation are confirmed in vivo, analysis of
cultured cells should provide significant mechanistic insight.
For example, if cultured p21-null SMCs and/or macrophages
disclose higher proliferative capacity than wild-type cells,
one may speculate that reduced inflammatory response as a
result of macrophage p21 deficiency (see above) might
compensate in vivo for the intrinsic higher proliferative
capacity of p21-deficient cells, thus resulting in similar BrdU
incorporation rates within the atheroma of p21/apoE/ and
p21/apoE/ mice. Given that activation of cyclin D/CDK
holoenzymes is actually facilitated by their interactions with
p21 and p27,16 it is also plausible that p21 disruption results
in impaired cell growth. Thus, lack of p21 might contribute to
limited atherosclerosis in p21/apoE/ mice by inhibiting
cell proliferation as a result of reduced cyclin D–associated
CDK activity.
The balance between cell proliferation and apoptotic cell
death is a chief determinant of neointimal thickening and
stability.17 p53 and p21 are important molecules in both cell
proliferation and apoptosis. As discussed below, studies in
different genetic murine models have yielded confounding
results about the specific role of p53 and p21, as well as their
interplay, in the regulation of neointimal hyperplastic growth
and apoptotic cell death.7–9,18 Not only does p53 inactivation
accelerate aortic atherosclerosis, it also leads to vulnerable-
appearing plaques. Remarkably, similar to the effect of p53
disruption, adenovirus-mediated overexpression of p53 in
preexisting carotid atherosclerotic lesions of apoE-null mice
induces features of vulnerable plaque, and this correlates with
an increase in fibrous cap cell apoptosis.19 Likewise,
adenovirus-dependent p53 gene transfer in isolated segments
of balloon-injured rat carotid arteries increased apoptosis.20 In
the Merched and Chan study,12 p21 deficiency resulted in an
2-fold increase in apoptosis within the lesion, affecting
primarily the macrophage population (although the frequency
of TUNEL-positive plaque cells was very low in both groups
of mice), yet analysis of similar-sized lesions revealed thicker
and better-formed fibrous caps and lower expression of
indicators of ruptured plaques in p21/apoE/ compared
with p21/apoE/ counterparts. As pointed out by the
authors, the proliferative and apoptotic responses are proba-
bly uncoupled in p21/apoE/ mice. Moreover, the authors
considered the possibility that a redundancy of factors might
take over some of the functions of p21. Indeed, they found
that transcripts for p16, pRB, and p53 were significantly
elevated in p21-null macrophages, suggesting that upregula-
tion of these growth suppressors might compensate for the
absence of the inhibitory effect of p21.
Conclusions and Future Perspective
The evidence accumulated over the last years lent support to
the notion that p21, p53, p57, and p27 can limit neointimal
thickening in animal models of atherosclerosis and angio-
plasty (Table).7–12,19,26–40 On the basis of immunohistopatho-
logical studies,21–25 these factors have also been considered as
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negative regulators of cell proliferation in human atheroscle-
rotic and restenotic lesions, and their overexpression has been
generally proposed as a promising approach to treat or
prevent these diseases.5,6 However, the common perception
of p21 as an atheroprotective factor is now challenged by the
unexpected acceleration of atherosclerosis in p21/apoE/
mice.12 It is now evident that p21 may control more than the
cell cycle, because major differences in inflammatory marker
gene expression exist between macrophages isolated from
p21-null and those isolated from wild-type animals. This
novel “inflammatory” aspect of p21 function may contribute
to its proatherogenic role in hypercholesterolemic mice.
Bearing in mind these new findings, it is tempting to
speculate that arterial expression of a subset of growth
suppressors (ie, p53 and p27) may be beneficial, whereas
other factors (ie, p21) may facilitate lesion development
and/or vulnerability to rupture. This question is certainly
difficult to address, particularly in relation to human disease;
however, there is still much to be learned from experimental
animals. Because lack of p21 expression is not likely to
represent the usual scenario in human atheromas, it would be
of interest to investigate atherosclerosis development in the
presence of varying levels of p21 expression. This can be
achieved by comparing, in different genetic and dietary
models, the phenotype of p21 transgenic and p21/ mice
versus that of controls with normal p21 gene dosage. Another
important consideration is that whole-body inactivation of
p21 is unlikely to occur in patients, and therefore, future
studies on the role of p21, and other cell cycle–regulatory
factors such as p27 and p53, should include the analysis of
mice with genetic manipulation restricted to specific cell
types involved in atherosclerosis (ie, endothelial cells, SMCs,
lymphocytes, and monocytes/macrophages). In addition, de-
spite the obvious limitations of descriptive studies, analysis of
a large number of human atherosclerotic and restenotic
specimens should help clarify the roles of p21, p27, and p53
in various aspects of human neointimal thickening, including
the inflammatory response elicited by immune cells.
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